Table 1.
Sample | AmplificationMethod |
Starting materials |
Amplified RNA(ng) | 3Amplification Fold (X) | |
Total RNA (ng) (1mRNA) | 2Cell number | ||||
Fresh MKN45 | 690 | 152.2 | 761 X | ||
4T7 IVT only | 20 (0.2) | ||||
SNU484 | 650 | 213.2 | 1066 X | ||
Fixed MKN45 | 830 | 121.6 | 608 X | ||
T7 IVT only | 20 (0.2) | ||||
SNU484 | 1090 | 128.6 | 643 X | ||
MKN45 | 830 | 42120 | 210600 X | ||
5PCR-T7 IVT | 20 (0.2) | ||||
SNU484 | 1090 | 45016 | 225080 X |
RNAs from fresh and formalin-fixed xenograft tumors of MKN45 and SNU484 cells were amplified under the same conditions as described in the Materials and Methods.
mRNA : estimated to be 1/100 of total RNA (ng). 2Cell number: estimated number of cells from tissue sections required to obtain the starting RNA (20ng). 3Amplification folds: aRNA/estimated starting mRNA.
T7 IVT: in vitro transcription using T7 RNA polymerase.
PCR-T7 IVT: 20 cycles of PCR followed by T7 IVT.